ADRB2 and neoplasm: Pre-clinically, we found that blocking the β2-AR signaling, STAT-3 signaling or ATP and Itaconate metabolites results in enhancement of doxorubicin chemotherapy, marked by reduced tumor growth and increased survival in the EL4 murine lymphoma model.